

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Olaparib with abiraterone for untreated hormone- relapsed metastatic prostate cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

(when no draft guidance was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

<p>During the scoping process, it was highlighted that olaparib with abiraterone is indicated for people for whom chemotherapy is not clinically indicated. It was noted that people who cannot or should not have chemotherapy are likely to be older.</p>

<p>The committee is only able to consider recommendations for olaparib with abiraterone within its marketing authorisation.</p>

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

<p>Several additional potential equality considerations were highlighted:</p>

- | |
|---|
| <ul style="list-style-type: none">• Prostate cancer disproportionately affects men of a Black African ethnicity• People from an Ashkenazi Jewish ethnicity have a 10x greater risk of having a BRCA mutation |
|---|

- People who have a prostate and do not identify as men can develop prostate cancer
- An oral treatment regime can be more acceptable to people with dementia or learning difficulties than an invasive treatment like chemotherapy. The medications can be supplied in the post to those unable to travel to get treatment

The committee considered these issues and was aware of the benefits of oral treatment, but concluded that there were no specific adjustments required to the NICE methods in this circumstance.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

Differences in the incidence and prevalence cannot not addressed in a Technology Appraisal. Recommendations are written in gender neutral language so that the recommendation applies equally to all people with prostates, including those who do or do not identify as men

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with,

access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes. Please see final draft guidance section 3.15.

Approved by Associate Director (name): Ian Watson

Date: 06/12/2023